2025-12-19 - Analysis Report
Okay, here's a comprehensive report on Eli Lilly (LLY), incorporating the data provided, with simple numbers and analyses for each section, culminating in a summary.

**1. Return Rate Comparison**

*   **Ticker:** LLY (Eli Lilly and Co)
*   **Overview:** Eli Lilly is a global pharmaceutical company focused on discovering, developing, and marketing pharmaceutical products.
*   **LLY Cumulative Return:** 300.11%
*   **VOO (S&P 500) Cumulative Return:** 99.09%
*   **Divergence:**
    *   Current Divergence: 199.3
    *   Relative Divergence: 82.6

**Analysis:**  Eli Lilly has significantly outperformed the S&P 500 (VOO). The cumulative return is substantially higher.  The relative divergence of 82.6 indicates that the current difference in returns is high compared to the historical range of divergence between LLY and VOO.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2015-2017  | 11.0%   | 76.1%   | -17.0%  | -0.0  | 75.7   |
| 2016-2018  | 39.0%   | 68.9%   | 24.0%   | -0.0  | 103.7  |
| 2017-2019  | 41.0%   | 68.9%   | 19.0%   | 0.4   | 117.8  |
| 2018-2020  | 34.0%   | 79.8%   | 10.0%   | 0.4   | 151.4  |
| 2019-2021  | 53.0%   | 79.8%   | 7.0%    | 0.5   | 247.6  |
| 2020-2022  | 64.0%   | 79.8%   | 65.0%   | 0.4   | 328.0  |
| 2021-2023  | 125.0%  | 78.9%   | 124.0%  | 0.2   | 522.6  |
| 2022-2024  | 134.0%  | 81.2%   | 113.0%  | 0.2   | 692.1  |
| 2023-2025  | 191.0%  | 83.5%   | 128.0%  | 0.2   | 947.5  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows strong growth, particularly in recent years.
*   **MDD:** The Maximum Drawdown indicates the potential downside risk, which is relatively high across all periods.
*   **Alpha:** Alpha, representing excess return relative to the benchmark, is positive in most periods, especially strong recently.  This suggests LLY's performance is due to factors other than just market movement.
*   **Beta:** Beta values are generally low, indicating lower volatility compared to the market. It's close to 0, implying it does not move in direct correlation with the market.
*   **Cap(B):**  Market capitalization has grown significantly.

**2. Recent Stock Price Fluctuations**

*   **Close:** 1056.88
*   **Last Market Data:**
    *   Price: 1056.88
    *   Previous Close: 1041.79
    *   Change: 1.45%
*   **5-day SMA:** 1048.53
*   **20-day SMA:** 1041.15
*   **60-day SMA:** 925.23

**Analysis:**  The stock price is above all three moving averages, suggesting an uptrend. The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, reinforcing this bullish signal. The recent positive change indicates continued upward momentum.

**3. RSI, PPO Index Indicators, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 45.68
*   **PPO:** -0.41
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent (20 days) relative divergence change:** 10.1 (+) (Short-term increase)
*   **Expected Return (%):** 51.6% (Expected excess return compared to S&P 500 if invested long-term)

**Analysis:**

*   **MRI:** A medium investment rating suggests a balanced risk-reward profile.
*   **RSI:** An RSI of 45.68 is neutral, not indicating overbought or oversold conditions.
*   **PPO:** A slightly negative PPO indicates the short-term moving average is slightly below the long-term moving average.
*   **Hybrid Signal:** Recommends buying with all available cash, and the MRI suggests a relatively safe investment environment.
*   **Expected Return:**  The high expected return suggests significant potential for future gains relative to the S&P 500.
*   **Recent Divergence Change:** The increasing relative divergence in the last 20 days suggests a strengthening outperformance of LLY compared to the benchmark.

**4. Recent News & Significant Events**

*   **Retatrutide Breakthrough, Orforglipron FDA Timeline:** Positive news about potential blockbuster drugs.
*   **Eli Lilly's Stock Outperforming Nvidia:**  Highlights LLY's recent strength.
*   **Bank of America Says Market Isn't Pricing in Weight-Loss Drug Dominance:** Suggests further upside potential.
*   **Where Will Eli Lilly Be in 10 Years?:** Long-term outlook being considered.
*   **3 Healthcare Giants Just Raised Dividends:**  Positive for income-seeking investors.
*   **Why Is Novo Nordisk Stock Falling?:** Important competitive context in the weight-loss drug market.

**Analysis:**  The news headlines are predominantly positive, focused on potential drug breakthroughs, outperformance, and future growth prospects. The news surrounding Novo Nordisk provides competitive context.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.70 (Buy)
*   **Opinions:** 27
*   **Target Price (avg/high/low):** 1093.22 / 1500.00 / 770.00

**Analysis:** The analyst consensus is strongly bullish, with a Buy rating and an average target price above the current price. The high target price suggests potential for further appreciation. No Recent Rating Changes (shown with empty arrows).

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-10-30 | 6.22  | 17.60 B$    |
| 2025-08-07 | 6.3   | 15.56 B$    |
| 2025-05-01 | 3.07  | 12.73 B$    |
| 2024-10-30 | 1.08  | 11.44 B$    |
| 2025-10-30 | 1.08  | 11.44 B$    |

**Analysis:**  Both EPS (Earnings Per Share) and revenue show strong growth in recent quarters. This indicates improving profitability and sales. EPS has significantly increased.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-09-30   | $17.60B  | 82.91%        |
| 2025-06-30   | $15.56B  | 84.27%        |
| 2025-03-31   | $12.73B  | 82.53%        |
| 2024-12-31   | $13.53B  | 82.24%        |
| 2024-09-30   | $11.44B  | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE      |
|--------------|----------|----------|
| 2025-09-30   | $23.79B  | 23.46%   |
| 2025-06-30   | $18.27B  | 30.98%   |
| 2025-03-31   | $15.76B  | 17.50%   |
| 2024-12-31   | $14.19B  | 31.07%   |
| 2024-09-30   | $14.24B  | 6.81%    |

**Analysis:**

*   **Revenue:**  Consistent and strong revenue growth is evident.
*   **Profit Margin:**  Very high and stable profit margins indicate excellent operational efficiency.
*   **Equity:** Equity has increased significantly, reflecting retained earnings.
*   **ROE:** Return on Equity is strong, reflecting the profitability of the company relative to shareholder equity.

**7. Comprehensive Analysis (Summary)**

Eli Lilly (LLY) presents a compelling investment case based on the provided data.

*   **Strong Performance:**  LLY has significantly outperformed the S&P 500, with a substantial cumulative return and increasing relative divergence.
*   **Growth:**  CAGR, Revenue, and EPS all demonstrate significant growth trends.
*   **Profitability:**  High and consistent profit margins and ROE underscore the company's financial strength.
*   **Market Sentiment:**  Positive news flow, strong analyst consensus, and a buy signal from the hybrid strategy indicate favorable market sentiment.
*   **Risk Factors:** High MDD values suggest higher risk.

**Overall Recommendation:**

Based on the provided data, Eli Lilly appears to be a promising investment opportunity. The company exhibits strong financial performance, positive market sentiment, and significant growth potential.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.